Investigation of GLP-2 Mechanism of Action (GA-8)

University of Copenhagen

Status: Completed

Conditions: Healthy

Treatments: Other: Placebo + GLP-2; Other: Placebo + Saline; Other: Placebo + GIP; Other: Inhibitor + GLP-2

Study type: Interventional

Funder types: Other

Identifiers

NCT03159741

GA-8-2017

Details and patient eligibility

About

Glucagon-like peptide-2 (GLP-2) is a naturally occuring hormone secreted to the circulation in response to food ingestion. Previous studies have shown that GLP-2 and incretins inhibit the bone resorption. However, the mechanism is unknown. In the present study we will investigate the mechanism of action using a receptor specific inhibitor.

Enrollment: 8 patients

Sex: Male

Ages: 20 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy, 20 to 40 years old, caucasian, BMI 18,5 to 24,9 kg/m2

Exclusion criteria

• Chronic disease, smoking, medication, weight change more than 3 kg whitin the last 3 months, overweight surgery, intestinal surgery, Hgb<8,0 mmol/L, decreased renal function.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

8 participants in 4 patient groups, including a placebo group

Inhibitor + GLP-2

Experimental group

Treatment:

Other: Inhibitor + GLP-2

Placebo + GLP-2

Experimental group

Treatment:

Other: Placebo + GLP-2

Placebo + GIP

Active Comparator group

Treatment:

Other: Placebo + GIP

Placebo + Saline

Placebo Comparator group

Treatment:

Other: Placebo + Saline